A detailed history of Peloton Wealth Strategists transactions in Exelixis, Inc. stock. As of the latest transaction made, Peloton Wealth Strategists holds 46,630 shares of EXEL stock, worth $1.55 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
46,630
Previous 47,830 2.51%
Holding current value
$1.55 Million
Previous $1.07 Million 12.66%
% of portfolio
0.49%
Previous 0.45%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$21.96 - $27.6 $26,352 - $33,120
-1,200 Reduced 2.51%
46,630 $1.21 Million
Q2 2024

Aug 15, 2024

SELL
$20.34 - $23.73 $20,340 - $23,730
-1,000 Reduced 2.05%
47,830 $1.07 Million
Q1 2024

May 14, 2024

BUY
$20.17 - $23.93 $33,885 - $40,202
1,680 Added 3.56%
48,830 $1.16 Million
Q4 2023

Feb 15, 2024

SELL
$19.25 - $24.13 $83,256 - $104,362
-4,325 Reduced 8.4%
47,150 $1.13 Million
Q3 2023

Nov 13, 2023

SELL
$19.04 - $22.74 $180,880 - $216,029
-9,500 Reduced 15.58%
51,475 $1.12 Million
Q2 2023

Aug 10, 2023

SELL
$18.17 - $20.48 $10,902 - $12,288
-600 Reduced 0.97%
60,975 $1.17 Million
Q1 2023

May 11, 2023

BUY
$16.3 - $19.41 $26,080 - $31,056
1,600 Added 2.67%
61,575 $1.2 Million
Q4 2022

Feb 13, 2023

BUY
$14.96 - $17.39 $44,880 - $52,170
3,000 Added 5.27%
59,975 $962,000
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $8,780 - $12,471
-560 Reduced 0.97%
56,975 $893,000
Q2 2022

Aug 12, 2022

BUY
$17.44 - $23.16 $39,240 - $52,110
2,250 Added 4.07%
57,535 $1.2 Million
Q1 2022

May 09, 2022

BUY
$17.03 - $22.67 $941,503 - $1.25 Million
55,285 New
55,285 $1.25 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Peloton Wealth Strategists Portfolio

Follow Peloton Wealth Strategists and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peloton Wealth Strategists, based on Form 13F filings with the SEC.

News

Stay updated on Peloton Wealth Strategists with notifications on news.